JNJ

Wall Street appears to be shifting out of winning technology stocks into parts of the market that have lagged, CNBC’s Jim Cramer said Monday. The “Mad Money” host detailed a strategy for investors to play the rotation that includes buying companies such as Morgan Stanley. “I’d rather find companies that did well in earnings season
0 Comments
Dr. Scott Gottlieb, a Pfizer board member, told CNBC that people should get their boosters as soon as possible because breakthrough infections are occurring more than the public realizes. The Centers for Disease Control and Prevention cleared Pfizer and Moderna boosters for all adults on Friday. The agency previously cleared Johnson & Johnson boosters. Anyone
0 Comments
The CDC still has to authorize distribution of the booster doses before people can start receiving the shots, which could start this weekend. The CDC’s independent panel of vaccine experts is scheduled to meet on Friday to review the new data. CDC Director Rochelle Walensky on Wednesday said the public health agency would “act swiftly”
0 Comments
Arkansas, Colorado, Louisiana, Kansas, Kentucky, Maine, New Mexico, Vermont and West Virginia are promoting the widespread rollout of boosters for any fully vaccinated adult. New York and Rhode Island are asking adults in high-transmission areas to get boosted, while New Jersey and Minnesota are planning to expand eligibility in the days ahead. California’s also asking
0 Comments
Moderna defended the use of its Covid-19 vaccine Thursday, saying the protection it offers against severe disease, hospitalization and death outweighs the risk of myocarditis, a rare heart condition seen in a small number of young men who received the shot. The company announced last week that the Food and Drug Administration needed more time
0 Comments
National Institutes of Health Director Dr. Francis Collins is advising fully vaccinated Americans to get their Covid booster shots to prevent breakthrough cases over the holidays, citing data from Israel that showed the waning effectiveness of Pfizer and BioNTech’s Covid-19 vaccine against the delta variant. The team from Technion-Israel Institute of Technology, Haifa, analyzed nearly
0 Comments
Emergent Biosolutions shares plunged after the company disclosed that the federal government had canceled its multimillion-dollar contract with the Covid-19 vaccine manufacturer. It was awarded a $628 million U.S. government contract last year to help make the shots. The company will forgo $180 million due to the contract’s termination, executives told investors on a call.
0 Comments
At least 1.5 million Americans received a booster shot of either Moderna’s or J&J’s Covid-19 vaccine in the first five days after U.S. regulators authorized the extra doses, a White House official said. “Our booster program is off to a very strong start,” Jeff Zients, the White House coronavirus response coordinator, told reporters. At least
0 Comments
More than 47 million Pfizer vaccine recipients who received both shots at least six months ago became eligible for a booster Friday. More than 39.1 million Moderna vaccine recipients who received both shots at least six months ago became eligible for a booster Friday. The CDC adopted a slightly different criteria for J&J’s one-shot Covid
0 Comments
Formally known as AY.4.2, the delta plus subvariant includes two new mutations to the spike protein, A222V and Y145H, which allow the virus to enter the body. The AY.4.2 subvariant has been detected in at least five cases in the U.S.: Washington, D.C., California, North Carolina, Washington state and Massachusetts. Francois Balloux, the director of
0 Comments
An influential CDC advisory committee on Thursday unanimously recommended boosters of Moderna and Johnson & Johnson’s Covid-19 vaccines. While the endorsement isn’t binding, CDC Director Dr. Rochelle Walensky is expected to give her final approval as early as this evening. More than 39 million Moderna recipients and nearly 13 million J&J recipients may be eligible
0 Comments
The Centers for Disease Control and Prevention on Thursday published data listing the most common side effects people reported after receiving boosters of Pfizer or Moderna’s Covid vaccine or a second dose of Johnson & Johnson‘s. The data, presented to the agency’s Advisory Committee on Immunization Practices, is based on submissions to the agency’s text
0 Comments
A Reddit channel called r/HermanCainAward is filled with stories of people who mocked Covid-19 vaccines before eventually dying from the disease. Since the subreddit’s creation in September 2020, it’s expanded to more than 375,000 members, with the top posts garnering thousands of user interactions. “It really hits home when you literally see yourself in these
0 Comments
Dr. Ofer Levy, a voting member of the FDA’s vaccine advisory panel, spoke with CNBC’s “Closing Bell” after the committee unanimously recommended the agency approve J&J’s Covid boosters. The panel previously recommended the FDA approve boosters from Moderna and Pfizer for anyone 65 and older, among other high-risk groups. Some committee members have voiced concern
0 Comments
Members of the Food and Drug Administration’s key advisory committee on vaccines criticized the speed with which the agency was reviewing Johnson & Johnson’s Covid booster trials as well as the lack of verified data presented before the panel Friday. Their comments came before the panel of outside experts unanimously voted to recommend the company’s
0 Comments
An influential Food and Drug Administration advisory committee on Friday said the agency should authorize boosters of Johnson & Johnson‘s single-shot Covid-19 vaccine to the more than 15 million Americans who have already received the initial dose. The unanimous vote – by the agency’s Vaccines and Related Biological Products Advisory Committee – is a critical
0 Comments
This is CNBC’s live blog covering the FDA’s Vaccines and Related Biological Products Advisory Committee meeting Friday to debate and vote on booster shots for Johnson & Johnson’s Covid vaccine. This blog will be updated throughout the day as the news breaks. The Food and Drug Administration’s key vaccine advisory panel meets Friday to discuss
0 Comments